Oxford, Evotec ramp up LAB10x with AI experts at Sensyne — focused on biotech spinouts
Oxford is allying itself with Evotec and artificial intelligence outfit Sensyne Health to ramp up some new biotech spinouts while looking to “accelerate data-driven drug discovery and development.”
The big idea here is that Oxford scientists — some of the best drug hunters in the world — can utilize Sensyne’s AI platform for their work, relying on the chemists and hands-on developers at Evotec to push ahead to a critical proof of concept moment. And they’ll do it through a project leader called LAB10x, which gets £5 million over the next three years to fund the work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
